Your browser doesn't support javascript.
loading
Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
Fujita, Noriko; Fujita, Koichi; Kim, Seung Jin; Iguchi, Chikage; Nomura, Takashi; Aono, Toyokazu; Yanagisawa, Tetsu; Enomoto, Yukie; Inakami, Keiko; Miyagawa, Yoshimasa; Tomoike, Riki; Kasugai, Tsutomu; Shiba, Eiichi.
Afiliación
  • Fujita N; Department of Breast and Endocrine Surgery, Osaka Breast Clinic, Osaka, Japan.
  • Fujita K; First Research Department, Tazuke Kofukai Medical Research Institute, Osaka, Japan.
  • Kim SJ; Department of Gastroenterology and Hepatology, Yodogawa Christian Hospital, Osaka, Japan.
  • Iguchi C; Department of Breast and Endocrine Surgery, Osaka Breast Clinic, Osaka, Japan.
  • Nomura T; Department of Breast and Endocrine Surgery, Osaka Breast Clinic, Osaka, Japan.
  • Aono T; Department of Breast and Endocrine Surgery, Osaka Breast Clinic, Osaka, Japan.
  • Yanagisawa T; Department of Breast and Endocrine Surgery, Osaka Breast Clinic, Osaka, Japan.
  • Enomoto Y; Department of Breast and Endocrine Surgery, Osaka Breast Clinic, Osaka, Japan.
  • Inakami K; Department of Breast and Endocrine Surgery, Osaka Breast Clinic, Osaka, Japan.
  • Miyagawa Y; Department of Breast and Endocrine Surgery, Osaka Breast Clinic, Osaka, Japan.
  • Tomoike R; Department of Breast and Endocrine Surgery, Osaka Breast Clinic, Osaka, Japan.
  • Kasugai T; Department of Breast and Endocrine Surgery, Osaka Breast Clinic, Osaka, Japan.
  • Shiba E; Department of Pathology, Osaka Breast Clinic, Osaka, Japan.
Oncology ; 100(5): 257-266, 2022.
Article en En | MEDLINE | ID: mdl-35114682
BACKGROUND: De-escalation therapy omitting anthracycline has been generally adopted for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the adjuvant setting, but not in the neoadjuvant chemotherapy (NAC) setting. We investigated whether anthracycline can be omitted in HER2-positive early breast cancer patients receiving neoadjuvant taxane plus trastuzumab with clinical response. METHODS: HER2-positive primary breast cancer patients treated using NAC containing trastuzumab were enrolled between September 2006 and July 2018 at Osaka Breast Clinic. The primary outcome was disease-free survival (DFS). The secondary outcome was overall survival (OS). We investigated survival with or without fluorouracil, epirubicin, and cyclophosphamide (FEC) using the log-rank test and propensity score matching (PSM). RESULTS: In total, 142 patients were retrospectively included and median follow-up was 61 months. There was no significant difference in DFS (p = 0.93) and OS (p = 0.46) between the FEC-omitted group and the FEC-added group. The 5-year DFS was 91% and 88% and OS was 100% and 100%, respectively. After PSM, the FEC-omitted group and the FEC-added group had no significant differences in DFS (p = 0.459) and there were no death events in either group. The 5-year DFS was 90% and 88% and OS was 100% and 100%, respectively. CONCLUSIONS: Using PSM, the 5-year DFS of HER2-positive early breast cancer was not different with or without anthracycline. Response-guided omission of anthracycline may be an option for HER2-positive early breast cancer patients receiving neoadjuvant taxane and trastuzumab with good response in order to avoid overtreatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Terapia Neoadyuvante Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Oncology Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Terapia Neoadyuvante Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Oncology Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza